Background: Treatment with an aldosterone antagonist (AA) has been shown in multiple trials to reduce heart failure (HF)-related morbidity, mortality, and hospital readmission. American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) treatment guidelines recommend the use of an AA in all HF patients with an ejection fraction ≤35% and no known contraindication. Several studies have documented underuse of AA. Objectives: To determine the proportion of patients who received AA therapy consistent with the ACCF/AHA guidelines. Secondary objectives included determining the proportion of patients who received an AA inconsistent with guidelines and 30- and 90-day readmission rates. Methods: A retrospective chart review was conducted of patients admitted to an inner city academic medical center with a diagnosis of HF between August 16, 2011, and June 5, 2013. Results: A total of 346 HF admissions (87.6% African American) were evaluated. Use of an AA at discharge was consistent with guidelines in 31% of patients. A total of 121 patients (35%) were discharged on an AA. Among the remaining 225 patients who were not discharged on an AA, 170 (75.6%) had no contraindication to therapy. Sixty-one patients were readmitted within 30 days, and a total of 108 patients were readmitted within 90 days. There were no significant differences in readmission rates between patients who were discharged on AA therapy and those who were not. Conclusion: AAs are still underutilized in the treatment of HF.
Background: Treatment with an aldosterone antagonist (AA) has been shown in multiple trials to reduce heart failure (HF)-related morbidity, mortality, and hospital readmission. American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) treatment guidelines recommend the use of an AA in all HF patients with an ejection fraction ≤35% and no known contraindication. Several studies have documented underuse of AA. Objectives: To determine the proportion of patients who received AA therapy consistent with the ACCF/AHA guidelines. Secondary objectives included determining the proportion of patients who received an AA inconsistent with guidelines and 30- and 90-day readmission rates. Methods: A retrospective chart review was conducted of patients admitted to an inner city academic medical center with a diagnosis of HF between August 16, 2011, and June 5, 2013. Results: A total of 346 HF admissions (87.6% African American) were evaluated. Use of an AA at discharge was consistent with guidelines in 31% of patients. A total of 121 patients (35%) were discharged on an AA. Among the remaining 225 patients who were not discharged on an AA, 170 (75.6%) had no contraindication to therapy. Sixty-one patients were readmitted within 30 days, and a total of 108 patients were readmitted within 90 days. There were no significant differences in readmission rates between patients who were discharged on AA therapy and those who were not. Conclusion: AAs are still underutilized in the treatment of HF.
Authors: Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt Journal: N Engl J Med Date: 2010-11-14 Impact factor: 91.245
Authors: Muthiah Vaduganathan; Alessandra Dei Cas; Robert J Mentz; Stephen J Greene; Sadiya Khan; Haris P Subacius; Ovidiu Chioncel; Aldo P Maggioni; Marvin A Konstam; Michele Senni; Gregg C Fonarow; Javed Butler; Mihai Gheorghiade Journal: Am J Cardiol Date: 2014-06-24 Impact factor: 2.778
Authors: Chakradhari Inampudi; Sridivya Parvataneni; Charity J Morgan; Prakash Deedwania; Gregg C Fonarow; Paul W Sanders; Sumanth D Prabhu; Javed Butler; Daniel E Forman; Wilbert S Aronow; Richard M Allman; Ali Ahmed Journal: Am J Cardiol Date: 2014-04-18 Impact factor: 2.778
Authors: Akshay S Desai; Orly Vardeny; Brian Claggett; John J V McMurray; Milton Packer; Karl Swedberg; Jean L Rouleau; Michael R Zile; Martin Lefkowitz; Victor Shi; Scott D Solomon Journal: JAMA Cardiol Date: 2017-01-01 Impact factor: 14.676
Authors: Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245
Authors: Patrick Rossignol; Daniela Dobre; John J V McMurray; Karl Swedberg; Henry Krum; Dirk J van Veldhuisen; Harry Shi; Michael Messig; John Vincent; Nicolas Girerd; George Bakris; Bertram Pitt; Faiez Zannad Journal: Circ Heart Fail Date: 2013-12-02 Impact factor: 8.790
Authors: Lesley H Curtis; Xiaojuan Mi; Laura G Qualls; Devon K Check; Bradley G Hammill; Stephen C Hammill; Paul A Heidenreich; Frederick A Masoudi; Soko Setoguchi; Adrian F Hernandez; Gregg C Fonarow Journal: Am Heart J Date: 2013-04-18 Impact factor: 4.749
Authors: Nancy M Albert; Clyde W Yancy; Li Liang; Xin Zhao; Adrian F Hernandez; Eric D Peterson; Christopher P Cannon; Gregg C Fonarow Journal: JAMA Date: 2009-10-21 Impact factor: 56.272